Theratechnologies Says Sudocetaxel Zendusortide ASCO 2024 Presentation Shows Signs Of Long-Term Efficacy And Manageable Safety Profile In Patients With Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies announced that their drug sudocetaxel zendusortide showed signs of long-term efficacy and a manageable safety profile in patients with solid tumors, according to an updated analysis from an ongoing Phase 1 clinical trial. The drug induced durable disease stabilization lasting up to 45 weeks beyond treatment completion.
May 23, 2024 | 9:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theratechnologies' sudocetaxel zendusortide has shown promising results in an ongoing Phase 1 clinical trial, indicating long-term efficacy and a manageable safety profile in patients with solid tumors. This could positively impact the company's stock price.
The positive results from the Phase 1 clinical trial of sudocetaxel zendusortide suggest potential for long-term efficacy and manageable safety in treating solid tumors. This is likely to boost investor confidence and positively impact the stock price of Theratechnologies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100